Drug Profile

Hepatitis A virus vaccine - Hard to Treat Diseases Inc/Zhejiang Pukang Biotechnology

Alternative Names: MEVAC-A

Latest Information Update: 02 Oct 2021

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Hard To Treat Diseases; Zhejiang Pukang Biotechnology
Developer Hard To Treat Diseases; Shenzhen Mellow Hope Pharm Industrial Co Ltd; Zhejiang Pukang Biotechnology
Class Hepatitis A vaccines
Mechanism of Action Immunostimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Marketed Hepatitis A

Most Recent Events

04 Nov 2017 No recent reports of development identified for clinical-Phase-Unknown development in Hepatitis-A(Prevention) in Vietnam
04 Jun 2010 Clinical trials in Hepatitis A prevention in Vietnam (unspecified route)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com